Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles

Bidding War May Ensue

 
• By Andrew McConaghie
  
Merck_New_Jersey
Merck & Co has enjoyed huge success with Keytruda, but needs to find ways to reduce its reliance on the blockbuster immunotherapy.

More from Business

More from Scrip